J. B. Chemicals & Pharmaceuticals Limited manufactures and markets various pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients in India and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||₹1,799.45|
|52 Week High||₹892.60|
|52 Week Low||₹1,984.75|
|1 Month Change||3.47%|
|3 Month Change||-5.33%|
|1 Year Change||72.11%|
|3 Year Change||491.83%|
|5 Year Change||371.68%|
|Change since IPO||35,252.66%|
Recent News & Updates
|506943||IN Pharmaceuticals||IN Market|
Return vs Industry: 506943 exceeded the Indian Pharmaceuticals industry which returned 23.5% over the past year.
Return vs Market: 506943 exceeded the Indian Market which returned 68.3% over the past year.
Stable Share Price: 506943 is less volatile than 75% of Indian stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: 506943's weekly volatility (4%) has been stable over the past year.
About the Company
J. B. Chemicals & Pharmaceuticals Limited manufactures and markets various pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients in India and internationally. The company manufactures a range of specialty products that include various pharmaceutical dosage forms. Its principal products include Cilnidipine, Ranitidine, and Metronidazole.
J. B. Chemicals & Pharmaceuticals Fundamentals Summary
|506943 fundamental statistics|
Is 506943 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|506943 income statement (TTM)|
|Cost of Revenue||₹7.53b|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||57.89|
|Net Profit Margin||21.04%|
How did 506943 perform over the long term?See historical performance and comparison
0.9%Current Dividend Yield
Is J. B. Chemicals & Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 506943 (₹1799.45) is trading above our estimate of fair value (₹1504.93)
Significantly Below Fair Value: 506943 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 506943 is poor value based on its PE Ratio (31.1x) compared to the Indian Pharmaceuticals industry average (26x).
PE vs Market: 506943 is poor value based on its PE Ratio (31.1x) compared to the Indian market (22.2x).
Price to Earnings Growth Ratio
PEG Ratio: 506943 is poor value based on its PEG Ratio (1.8x)
Price to Book Ratio
PB vs Industry: 506943 is overvalued based on its PB Ratio (7.7x) compared to the IN Pharmaceuticals industry average (3.2x).
How is J. B. Chemicals & Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 506943's forecast earnings growth (17.3% per year) is above the savings rate (6.7%).
Earnings vs Market: 506943's earnings (17.3% per year) are forecast to grow slower than the Indian market (19.2% per year).
High Growth Earnings: 506943's earnings are forecast to grow, but not significantly.
Revenue vs Market: 506943's revenue (14.3% per year) is forecast to grow faster than the Indian market (12.9% per year).
High Growth Revenue: 506943's revenue (14.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 506943's Return on Equity is forecast to be high in 3 years time (23.3%)
How has J. B. Chemicals & Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 506943 has a large one-off gain of ₹1.0B impacting its June 30 2021 financial results.
Growing Profit Margin: 506943's current net profit margins (21%) are higher than last year (17.8%).
Past Earnings Growth Analysis
Earnings Trend: 506943's earnings have grown significantly by 25.3% per year over the past 5 years.
Accelerating Growth: 506943's earnings growth over the past year (35.8%) exceeds its 5-year average (25.3% per year).
Earnings vs Industry: 506943 earnings growth over the past year (35.8%) underperformed the Pharmaceuticals industry 35.8%.
Return on Equity
High ROE: 506943's Return on Equity (24.7%) is considered high.
How is J. B. Chemicals & Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: 506943's short term assets (₹15.5B) exceed its short term liabilities (₹3.5B).
Long Term Liabilities: 506943's short term assets (₹15.5B) exceed its long term liabilities (₹794.1M).
Debt to Equity History and Analysis
Debt Level: 506943's debt to equity ratio (2.5%) is considered satisfactory.
Reducing Debt: 506943's debt to equity ratio has reduced from 12.8% to 2.5% over the past 5 years.
Debt Coverage: 506943's debt is well covered by operating cash flow (699.7%).
Interest Coverage: 506943's interest payments on its debt are well covered by EBIT (229.3x coverage).
What is J. B. Chemicals & Pharmaceuticals's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 506943's dividend (0.92%) is higher than the bottom 25% of dividend payers in the Indian market (0.33%).
High Dividend: 506943's dividend (0.92%) is low compared to the top 25% of dividend payers in the Indian market (1.35%).
Stability and Growth of Payments
Stable Dividend: 506943's dividend payments have been volatile in the past 10 years.
Growing Dividend: 506943's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (28.5%), 506943's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: 506943's dividends in 3 years are forecast to be well covered by earnings (20.8% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Mr. Nikhil Ashokkumar Chopra serves as Chief Executive Officer and Whole-Time Director at J. B. Chemicals & Pharmaceuticals Limited since December 23, 2020 and has been its Director since May 10, 2020. He...
CEO Compensation Analysis
Compensation vs Market: Nikhil's total compensation ($USD424.96K) is about average for companies of similar size in the Indian market ($USD421.99K).
Compensation vs Earnings: Insufficient data to compare Nikhil's compensation with company performance.
Experienced Board: 506943's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: 506943 insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
J. B. Chemicals & Pharmaceuticals Limited's employee growth, exchange listings and data sources
- Name: J. B. Chemicals & Pharmaceuticals Limited
- Ticker: 506943
- Exchange: BSE
- Founded: 1976
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹139.065b
- Shares outstanding: 77.28m
- Website: https://www.jbcpl.com
Number of Employees
- J. B. Chemicals & Pharmaceuticals Limited
- Cnergy IT Park
- Unit A2, 3rd floor & Unit A, 8th floor
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/17 12:03|
|End of Day Share Price||2021/10/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.